Every year, half a million Americans experience the sudden, life-altering reality of a nerve injury. Whether it’s a momentary lapse in judgment while chopping vegetables or a high-stakes accident in a woodshop, the aftermath is often the same: the quiet, frustrating loss of sensation. When a peripheral nerve is severed, the intricate communication lines that run from our brain to our fingertips are disconnected. For years, the gold standard for repair has been the micro-suture—a technique so delicate and demanding that even the most skilled surgeons struggle to achieve perfect alignment. When these nerves fail to reconnect precisely, the results are devastating, ranging from persistent, numbing coldness to sharp, electric jolts of chronic pain that can linger for a lifetime.
Enter the French startup Tissium, a company that is reimagining how we mend the human body by moving away from the “needle and thread” approach of the past. Their innovation is a sophisticated, bio-compatible liquid polymer, crafted from fatty acids and glycerol—substances the body already recognizes as its own. When a surgeon applies this thick, sticky substance to a damaged nerve and exposes it to a specific light, it instantly transforms into a secure, flexible splint. This liquid doesn’t just hold the tissue together; it provides a protective, stable environment where the nerve can breathe and regenerate on its own. Once the body has successfully knitted itself back together, the “glue” simply biodegrades, leaving no foreign hardware behind.
The clinical results from early trials have been nothing short of transformative. In a pilot study involving 12 patients with finger nerve injuries, the outcomes were remarkable:100 percent of the participants regained full sensation, including the ability to perceive temperature, pain, texture, and light touch. When you compare this to the roughly 80 percent success rate typical of traditional micro-suturing, the improvement is profound. Perhaps most importantly, none of these patients reported pain or device-related complications a full year after their procedures. For a modern surgeon, having an option that is both less traumatic to the tissue and more consistent in its application represents a major leap forward in regenerative medicine.
Tissium’s success has caught the attention of both the medical community and major investors. With over €60 million in combined venture capital and European Investment Bank funding secured, the company is rapidly scaling up its operations from its manufacturing base in northern France. Their product, which earned FDA marketing approval just last year, is already available for surgeons across the United States. Experts like Dr. Simran Chana from the University of Cambridge, who have watched these developments from the sidelines, note that while more data is always welcome, we are clearly entering a new era where advanced biomaterials are giving surgeons the tools to perform “biological” repairs rather than just mechanical ones.
The vision for this “goo,” as some affectionately call it, goes far beyond nerve repair. The company is currently leveraging its new funding to launch a massive US-based trial involving 200 patients focused on hernia repairs. Currently, fixing a hernia involves pushing tissue back through a muscle wall and pinning it down with heavy mesh and stitches, a process that can vary wildly depending on the surgeon’s hand. By introducing their consistent, light-activated adhesive to the process, Tissium hopes to standardize the recovery, reduce recurrence rates, and significantly lower the pain levels patients face during the healing phase. Early European data suggests that this approach is already leading to a better quality of life for those recovering from hernia surgery.
Looking toward the horizon, the potential applications for this technology seem almost limitless. Tissium’s cofounder, Maria Pereira, originally conceived of this bio-adhesive nearly two decades ago for the high-pressure, high-stakes world of cardiovascular reconstruction. Now, with the capital and momentum to pursue those original dreams, the company is preparing for a randomized, pivotal trial in the US to see if their liquid technology can mend heart-related tissues as effectively as it mends nerves. By daring to rethink the basic mechanics of surgery, Tissium isn’t just selling a medical product; they are offering a future where the body’s natural ability to heal is supported, guided, and restored with greater precision than ever before.
